This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Aventus Thrombectomy System Pulmonary Embolism Clinical Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05907564
Recruitment Status : Recruiting
First Posted : June 18, 2023
Last Update Posted : January 17, 2024
Sponsor:
Information provided by (Responsible Party):
Inquis Medical, Inc.

Brief Summary:
Evaluate the safety and efficacy of the Aventus Thrombectomy System for aspiration thrombectomy in subjects with acute pulmonary embolism.

Condition or disease Intervention/treatment Phase
Pulmonary Embolism Embolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Device: Thrombectomy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluate the Safety and Efficacy of the Aventus Thrombectomy System for Aspiration Thrombectomy in Subjects With Acute Pulmonary Embolism
Actual Study Start Date : September 20, 2023
Estimated Primary Completion Date : March 2025
Estimated Study Completion Date : March 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Single Arm
Device: Aventus Thrombectomy System
Device: Thrombectomy
Use of Aventus Thrombectomy System to treat pulmonary embolism




Primary Outcome Measures :
  1. Change in RV/LV Ratio [ Time Frame: From Baseline to 48 hours ]
    Change in RV/LV Ratio per CTA

  2. Major Adverse Event Rate [ Time Frame: From Index Procedure to 48 hours ]
    Composite of device related MAEs including death, major bleed, clinical deterioration, pulmonary vascular injury, and cardiac injury



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 and ≤ 80 years
  2. Subject or legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures
  3. Subject is willing and able to comply with all protocol required follow-up visits
  4. PE symptom(s) duration ≤ 14 days from index procedure
  5. PE diagnosis ≤ 48 hours prior to index procedure
  6. CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery based on Investigator determination)
  7. CTA evidence of dilated RV with an RV/LV ratio of ≥ 0.9 at baseline based on Investigator determination
  8. Systolic blood pressure ≥ 90 mmHg without need for vasopressors (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mmHg with intravenous fluids prior to index procedure)
  9. Stable heart rate < 130 BPM prior to index procedure
  10. Subject is deemed medically eligible for interventional procedure(s), per institutional guidelines and clinical judgment

Exclusion Criteria:

  1. Prior PE ≤ 180 days from index procedure
  2. Current hospitalization for other condition(s)
  3. Thrombolytic use ≤ 14 days of baseline CTA
  4. Pulmonary hypertension with peak pulmonary artery systolic pressure > 70 mmHg by right heart catheterization
  5. FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%
  6. Hematocrit < 28% within 6 hours of index procedure
  7. Platelets < 100,000/μL
  8. Serum creatinine > 1.8 mg/dL
  9. International normalized ratio (INR) > 3
  10. Presence of intracardiac lead in the right ventricle or right atrium placed < 180 days prior to index procedure
  11. Cardiovascular or pulmonary surgery ≤ 7 days prior to index procedure
  12. Actively progressing cancer treated by chemotherapeutics
  13. Known bleeding diathesis or coagulation disorder
  14. Left bundle branch block
  15. History of severe or chronic pulmonary arterial hypertension
  16. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
  17. History of uncompensated heart failure
  18. History of underlying lung disease that is oxygen dependent
  19. History of chest irradiation
  20. History of heparin-induced thrombocytopenia (HIT)
  21. Any contraindication to systemic or therapeutic doses of heparin or anticoagulants
  22. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
  23. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for aspiration thrombectomy intervention such as the inability to navigate to target location, predominantly chronic clot or non-clot embolus
  24. Life expectancy of < 90 days, as determined by Investigator
  25. Female who is pregnant or nursing
  26. Current participation in another investigational drug or device treatment study that has not reached the primary endpoint or the Investigator feels would impact their ability to participate in this clinical trial
  27. Subject has known residual Iliac Deep Vein Thrombosis (DVT), Inferior Vena Cava (IVC) clot or clot in transit (right atrium and/or right ventricular)
  28. Subject on extracorporeal membrane oxygenation (ECMO)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05907564


Contacts
Layout table for location contacts
Contact: Marc Penna 978-760-0311 clinical@inquismedical.com

Locations
Layout table for location information
United States, California
MemorialCare Recruiting
Long Beach, California, United States, 90806
Contact: Marc Penna       marc@inquismedical.com   
Contact: Jessica Hobson       jessica@inquismedical.com   
Principal Investigator: David Shavelle, MD         
Sub-Investigator: Khiet Hoang, MD         
Sub-Investigator: Aditya Prasad, MD         
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Marc Penna       marc@inquismedical.com   
Contact: Jessica Hobson       jessica@inquismedical.com   
Principal Investigator: Dan Schimmel, MD         
Sub-Investigator: Keith Benzuly, MD         
Sub-Investigator: James Flaherty, MD         
Ascension Illinois Recruiting
Elk Grove Village, Illinois, United States, 60007
Contact: Marc Penna       marc@inquismedical.com   
Contact: Jessica Hobson       jessica@inquismedical.com   
Principal Investigator: Alexander Fraley, MD         
Sub-Investigator: Paul Grunenwald, MD         
Sub-Investigator: Thomas O'Connell, MD         
Sub-Investigator: Andrei Pop, MD         
Sub-Investigator: Bharat Samy, MD         
United States, Ohio
University Hospitals Recruiting
Cleveland, Ohio, United States, 44106
Contact: Marc Penna       marc@inquismedical.com   
Contact: Jessica Hobson       jessica@inquismedical.com   
Principal Investigator: Jun Li, MD         
Sub-Investigator: Yulanka Castro-Dominguez, MD         
Sub-Investigator: Tarek Hammad, MD         
OhioHealth Research Institute Recruiting
Columbus, Ohio, United States, 43214
Contact: Marc Penna       marc@inquismedical.com   
Contact: Jessica Hobson       jessica@inquismedical.com   
Principal Investigator: Michael Jolly, MD         
Sub-Investigator: Christopher Huff, MD         
Sub-Investigator: Joseph Campbell, MD         
Sub-Investigator: John Philips, MD         
ProMedica - Jobst Vascular Recruiting
Toledo, Ohio, United States, 43606
Contact: Marc Penna       marc@inquismedical.com   
Contact: Jessica Hobson       jessica@inquismedical.com   
Principal Investigator: Ahmad Younes, MD         
Sub-Investigator: Jihad Abbas, MD         
Sub-Investigator: Brett Aplin, MD         
Sponsors and Collaborators
Inquis Medical, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Jun Li, MD University Hospitals
Principal Investigator: Saher Sabri, MD MedStar Health
Layout table for additonal information
Responsible Party: Inquis Medical, Inc.
ClinicalTrials.gov Identifier: NCT05907564    
Other Study ID Numbers: CT-0001
First Posted: June 18, 2023    Key Record Dates
Last Update Posted: January 17, 2024
Last Verified: January 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Inquis Medical, Inc.:
Pulmonary Embolism
Clot
Thromboembolism
Thrombectomy
Right Heart Strain
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Pulmonary Embolism
Respiratory Tract Diseases
Cardiovascular Diseases
Thrombosis
Embolism
Vascular Diseases
Embolism and Thrombosis